Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors

ClinicalTrials.gov ID: NCT00421733

Public ClinicalTrials.gov record NCT00421733. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

VITAL Study - Selective VITamin D Receptor Activator (Paricalcitol) for Albuminuria Lowering Study: A Phase 2, Prospective, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules on Reducing Albuminuria in Type 2 Diabetic Nephropathy Subjects Who Are Currently Being Treated With Renin-angiotensin System Inhibitors

Study identification

NCT ID
NCT00421733
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Abbott
Industry
Enrollment
281 participants

Conditions and interventions

Interventions

  • Zemplar (paricalcitol) capsules Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
20 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2006
Primary completion
May 31, 2009
Completion
May 31, 2009
Last update posted
Jan 19, 2012

2006 – 2009

United States locations

U.S. sites
27
U.S. states
15
U.S. cities
24
Facility City State ZIP Site status
Site Reference ID/Investigator# 862 Phoenix Arizona 85012
Site Reference ID/Investigator# 864 Fountain Valley California 92708
Site Reference ID/Investigator# 7291 Yuba City California 95991
Site Reference ID/Investigator# 853 Hudson Florida 34667
Site Reference ID/Investigator# 867 Lauderdale Lakes Florida 33313
Site Reference ID/Investigator# 857 Pembroke Pines Florida 33028
Site Reference ID/Investigator# 8901 West Palm Beach Florida 33401
Site Reference ID/Investigator# 7113 Roswell Georgia 30076
Site Reference ID/Investigator# 2531 Chicago Illinois 60654
Site Reference ID/Investigator# 3371 Evanston Illinois 60201
Site Reference ID/Investigator# 869 Indianapolis Indiana 46202
Site Reference ID/Investigator# 8054 Baton Rouge Louisiana 70808
Site Reference ID/Investigator# 854 Rockville Maryland 20852
Site Reference ID/Investigator# 6281 Boston Massachusetts 02215
Site Reference ID/Investigator# 859 Brooklyn Center Minnesota 55430
Site Reference ID/Investigator# 7214 Omaha Nebraska 68131
Site Reference ID/Investigator# 8046 Albany New York 12206
Site Reference ID/Investigator# 866 Charlotte North Carolina 28208
Site Reference ID/Investigator# 8039 Greenville North Carolina 27834
Site Reference ID/Investigator# 8053 Morehead City North Carolina 28557
Site Reference ID/Investigator# 6626 Winston-Salem North Carolina 27103
Site Reference ID/Investigator# 7495 Carlisle Pennsylvania 17015
Site Reference ID/Investigator# 9061 Dallas Texas 75230
Site Reference ID/Investigator# 8325 Dallas Texas 75231
Site Reference ID/Investigator# 856 Dallas Texas 75390
Site Reference ID/Investigator# 7494 San Antonio Texas 78229
Site Reference ID/Investigator# 774 San Antonio Texas 78229

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 45 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00421733, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 19, 2012 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00421733 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →